Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications

References

• BerrySJCoffeyDSWalshPCEwingLLThe development of human benign prostatic hyperplasia with ageJ Urol19841324744796206240
   PubMed Web of Science ®Google Scholar
• GarrawayWMCollinsGNLeeRJHigh prevalence of benign prostatic hypertrophy in the communityLancet19913384694711714529
   PubMed Web of Science ®Google Scholar
• McVaryKTRoehrbornCGAvinsALUpdate on AUA guideline on the management of benign prostatic hyperplasiaJ Urol20111851793180321420124
   PubMed Web of Science ®Google Scholar
• MadersbacherSAlivizatosGNordlingJEAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)Eur Urol20044654755415474261
   PubMed Web of Science ®Google Scholar
• McVaryKTAlfuzosin for symptomatic benign prostatic hyperplasia: long-term experienceJ Urol2006175354216406865
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBruskewitzRNickelGCUrinary retention in patients with BPH treated with finasteride or placebo over 4 years – characterization of patients and ultimate outcomesEur Urol20003752853610765090
   PubMed Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet200536521722315652604
   PubMed Web of Science ®Google Scholar
• MondainiNGiubileiGUngarAAlfuzosin (10mg) does not affect blood pressure in young healthy menEur Urol2006501292129816837126
   PubMed Web of Science ®Google Scholar
• KaplanSAUroselective alpha-blockade for benign prostatic hyperplasia: clinically significant or marketing savvy?Urology19995477677910565732
   PubMed Web of Science ®Google Scholar
• ChauLHTaiDCFungBTLiJCFanCWLiMKMedical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10 mm: a prospective randomized controlled trialInt J Urol20111851051421592234
   PubMed Web of Science ®Google Scholar
• AhmedAFAl-SayedAYTamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: prospective, randomized, comparative studyKorean J Urol20105119319720414396
   PubMedGoogle Scholar
• MehikAAlasPNickelJCSarpolaAHelströmPJAlfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot studyUrology20036242542912946740
   PubMed Web of Science ®Google Scholar
• BasarMMAtanAOzerginOYildizMThe efficacy of alfuzosin treatment in patients with prostatismInt Urol Nephrol20013349349712230279
   PubMedGoogle Scholar
• RoweESmithCLaverickLElkabirJWitherowROPatelAA prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followupJ Urol20051732044204715879822
   PubMed Web of Science ®Google Scholar
• MichelMCHeemannUSchumacherHMehlburgerLGoepelMAssociation of hypertension with symptoms of benign prostatic hyperplasiaJ Urol20041721390139315371852
   PubMed Web of Science ®Google Scholar
• AUA Practice Guidelines CommitteeAUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendationJ Urol20031702 Pt 153054712853821
   PubMed Web of Science ®Google Scholar
• SongKChooMSLeeKSThe long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractilityUrology2011771177118221256567
   PubMed Web of Science ®Google Scholar
• VallancienGEmbertonMAlcarazAALF-ONE Study GroupAlfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practiceBJU Int200810184785218321317
   PubMed Web of Science ®Google Scholar
• RoehrbornCGAlfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled studyBJU Int20069773474116536764
   PubMed Web of Science ®Google Scholar
• NickelJCElhilaliMEmbertonMVallancienGAlf-One Study GroupThe beneficial effect of alfuzosin 10 mg once daily in ‘real-life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculationBJU Int2006971242124616686719
   PubMed Web of Science ®Google Scholar
• NordlingJEfficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasiaBJU Int2005951006101215839922
   PubMed Web of Science ®Google Scholar
• MottetNBressolleFDelmasVRobertMCostaPProstatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administrationEur Urol20034410110512814682
   PubMed Web of Science ®Google Scholar
• ElhilaliMEmbertonMMatzkinHLong-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in ‘real-life’ practiceBJU Int20069751351916469018
   PubMed Web of Science ®Google Scholar
• RoehrbornCVan KerrebroeckPNordlingJSafety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studiesBJU Int20039225726112887479
   PubMed Web of Science ®Google Scholar
• van KerrebroeckPJardinAvan CanghPLavalKUALFORTI Study GroupLong-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension studyEur Urol200241546011999466
   PubMed Web of Science ®Google Scholar
• LeeSHParkKKMahSYEffects of alpha-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concomitant hypertensionProstate Cancer Prostatic Dis20101333333720567256
   PubMed Web of Science ®Google Scholar